December 11th 2020
As the biology of renal cell carcinoma becomes better understood, so does the management of the disease, including the use of novel therapies.
December 18th 2020
Advice to health care providers on when to refer patients for further assessment of potential renal cell carcinoma and insight on the types of diagnostic tests used to help confirm a diagnosis in the era of molecular testing.
Guidelines and recommendations by clinicians on treatment approaches for newly diagnosed renal cell carcinoma and regimens in the pipeline that may impact future treatment.
December 23rd 2020
A historical overview regarding the development of parameters used to help stratify risk in patients with renal cell carcinoma and the relevance of current models in the context of selecting systemic therapy to treat appropriate patients.
Preferred treatment regimens that incorporate novel therapies used to treat patients with metastatic renal cell carcinoma based on risk status.
January 8th 2021
The importance of risk assessment when selecting frontline therapy to treat advanced renal cell carcinoma and factors to consider when talking with patients about goals of therapy.
Drs Robert Alter and Robert Motzer discuss the rationale and use of surgery as supportive care to treat appropriate patients with metastatic renal cell carcinoma.
January 15th 2021
Variables that influence an individualized first-line treatment approach for advanced renal cell carcinoma.
Factors that prompt oncologists to move to second-line therapy to treat metastatic renal cell carcinoma.
January 22nd 2021
Oncologists discuss their preferences in regard to second-line therapy for metastatic renal cell carcinoma, and optimal timing for changing regimens based on responses to treatment.
